Program Trains Community Opinion Leaders in Principles of Pain Control

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

DULUTH, Minn-Effective strategies to improve cancer pain management in the community may be elusive, but researchers from the Minnesota Cancer Pain Project, led by Thomas E. Elliott, MD, believe they are on the right track with an intervention program that combines education of community opinion leaders with community outreach programs.

DULUTH, Minn-Effective strategies to improve cancer pain managementin the community may be elusive, but researchers from the MinnesotaCancer Pain Project, led by Thomas E. Elliott, MD, believe theyare on the right track with an intervention program that combineseducation of community opinion leaders with community outreachprograms.

To evaluate the program, the researchers randomly assigned threepairs of matched communities to receive either intervention orno intervention, Project Director Karen Johnson, MPH, of the DuluthClinic, said at her Congress poster presentation.

Opinion leader educators (physicians, nurses, pharmacists, socialworkers, and clergy) from the intervention areas participatedin a 2-day minifellowship that included lectures, clinical andhospice rounds, and preceptorships; they then returned to theircommunities to set up a task force of other educators, to diffusethe message and train their peers. This strategy was reinforcedwith community outreach education programs.

The results showed positive trends in the intervention communitiestoward reduced pain prevalence and improvement in physicians'and nurses' knowledge and attitude scores, but none reached significance.

Although the quantitative data were not statistically significant,Ms. Johnson believes the qualitative data, derived from surveysof task force members, suggest that the intervention produced"a much larger shift in behaviors than could be demonstratedwith the instruments that we used."

The task force members reported that previously unavailable painassessment tools were now being used, and pain protocols werebeing instituted. "We believe this type of intervention,trying to change patient pain levels by educating the people whotreat them, should prove effective in future intervention studies,"Ms. Johnson said.

Recent Videos
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Related Content